SCINAI IMMUNOTHERAPEUTICS LT (SCNI)
US09073Q3039 - ADR
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Tuesday's session: top gainers and losers
Why Is AMC Networks (AMCX) Stock Down 11% Today?
AMC Networks stock is down on Monday after AMCX investors learned of a $125 million private offering of convertible senior notes.
Why Is Kaival Brands Innovations (KAVL) Stock Down 33% Today?
Kaival Brands Innovations stock is down on Monday after shares of KAVL underwent a massive rally on Friday that sent it over 300% higher!
Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today?
ENDRA Life Sciences stock is up on Monday with heavy trading of NDRA shares following a shareholder update from the company.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?
Scinai Immunotherapeutics stock is up on Monday with heavy trading of SCNI shares despite a lack of news from the company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We have all of the biggest pre-market stock movers that investors are going to want to keep an eye on for Monday morning!
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023
Scinai Immunotherapeutics just reported results for the fourth quarter of 2023.
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (the "Company") (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology...
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological...
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological...
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological...
Scinai Immunotherapeutics files to sell 5.36M ADS for holders (NASDAQ:SCNI)
Read about Scinai Immunotherapeutics' latest filing of a prospectus, outlining its financial offering.
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I)...
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I)...